Abstract
Many studies have shown that 20% human albumin solution infusions improve circulatory function in patients with advanced liver disease, and this treatment is widely recommended and used by all hepatologists. However, it is more expensive than other crystalloids or colloids, and several countries suffer shortages of supply. This article examines whether other fluids might be considered for these patients.
Copyright © 2018 by the American Association for the Study of Liver Diseases.
MeSH terms
-
Clinical Trials as Topic
-
Colloids
-
Crystalloid Solutions / administration & dosage
-
Crystalloid Solutions / economics
-
End Stage Liver Disease / complications
-
End Stage Liver Disease / therapy*
-
Fluid Therapy / economics
-
Fluid Therapy / methods*
-
Fluid Therapy / standards
-
Humans
-
Infusions, Intravenous
-
Liver Transplantation
-
Plasma Substitutes / administration & dosage
-
Plasma Substitutes / economics
-
Practice Guidelines as Topic
-
Serum Albumin, Human / administration & dosage*
-
Serum Albumin, Human / adverse effects
-
Serum Albumin, Human / economics
-
Treatment Outcome
Substances
-
Colloids
-
Crystalloid Solutions
-
Plasma Substitutes
-
Serum Albumin, Human